Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDR-103
- Development stage
- Discontinued
- Lead developer
- Medeor Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
MDR-103 is an investigational personalized cellular immunotherapy developed by Medeor Therapeutics for the induction of functional immune tolerance in patients who have previously received a human leukocyte antigen (HLA)-matched, living donor kidney transplant. The therapy aims to establish mixed chimerism—a state where the donor's and recipient's immune systems coexist—thereby allowing for the reduction or complete withdrawal of chronic immunosuppressive medications. By eliminating the need for lifelong immunosuppression, MDR-103 seeks to reduce the risk of drug-related toxicities, infections, and malignancies while improving long-term graft survival.
Beyond the preview
Go deeper on MDR-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDR-103.